flow trial semaglutide kidney outcomes nejm 2024 hazard ratio Effects of on Chronic Disease in Patients with Type 2 Diabetes The rationale, design and baseline
Description
Real-world populations include a broader mix of patients, some healthier and some sicker than typical trial participants
Oral semaglutide (Rybelsus) is FDA-approved for type 2 diabetes management only, not for weight management
Wegovy contains a higher dose of semaglutide and is specifically FDA-approved for chronic weight in adults who are overweight
Help me so much by making me feel healthier
2) Wegovy will not work to help lose weight if you continue to eat deserts and sweets
e243474
